GLPwatch
A Study of LY3502970 in Healthy Overweight and Obese Participants
NCT05313802 · Completed
Last updated 2026-05-28This clinical trial tests the safety of the investigational drug LY3502970 in healthy adults who are overweight or obese.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind basic-science study
Participants 72 people
Who can join Ages 18–70 · all sexes Healthy volunteers accepted.
Timeline Started 2022-05 · est. completion 2022-09
Where 3 sites · United States
What this study is testing ClinicalTrials.gov NCT05313802 ↗
Description as written by the study sponsor.
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Treatments tested
- LY3502970 Drug
Administered orally.
| Main thing measured | Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Healthy, Obese |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05313802 ↗